

## Minutes of the Meeting of the Welsh Health Specialised Services Committee

held on 11 September 2018  
at Health and Care Research, Castlebridge 4,  
Cowbridge Road East, Cardiff

### Members Present:

Chris Turner	(CT)	In the Chair/ Independent Member
Carole Bell	(CB)	Director of Nursing and Quality Assurance, WHSSC
Stuart Davies	(SD)	Director of Finance, WHSSC
Gary Doherty (by VC)	(GD)	Chief Executive, Betsi Cadwaladr UHB
Vivienne Harpwood	(VH)	Chair (part meeting by telephone)
Sian Lewis	(SL)	Managing Director, WHSSC
Lyn Meadows	(LM)	Vice Chair (by VC)
Steve Moore	(SM)	Chief Executive, Hywel Dda UHB
Tracy Myhill	(TM)	Chief Executive, Abertawe Bro Morgannwg UHB
Judith Paget	(JP)	Chief Executive, Aneurin Bevan UHB
Len Richards	(LR)	Chief Executive, Cardiff and Vale UHB
Carol Shillabeer	(CS)	Chief Executive, Powys THB
Jennifer Thomas	(JT)	Medical Director, WHSSC
Allison Williams	(AW)	Chief Executive, Cwm Taf UHB
John Williams	(JW)	Associate Member/ Chair of the Welsh Clinical Renal Network

### Apologies:

Steve Ham	(SH)	Chief Executive, Velindre NHS Trust
Charles Janczewski	(CJ)	Independent Member/ Chair of the WHSSC Quality and Patient Safety Committee

### In Attendance:

Andrew Champion	(AC)	Assistant Director, Evidence, Evaluation & Effectiveness
Iolo Doull	(ID)	Deputy Medical Director, WHSSC
Ian Langfield	(IL)	Acting Director of Planning, WHSSC
Clare Nelson	(CN)	Acting Assistant Director of Planning, WHSSC
Kevin Smith	(KS)	Committee Secretary & Head of Corporate Services, WHSSC

### Observers:

Simon Dean		Welsh Government
Robert Mahoney	(RM)	Finance Manager, Cardiff and Vale UHB

### Minutes:

Michaella Henderson	(MH)	Corporate Governance Officer, WHSSC
The meeting opened at 09:30		

JC18/045	<p><b>Welcome, Introductions and Apologies</b></p> <p>CT formally opened the meeting and welcomed members, explaining that VH had asked him to chair the meeting because she would only be able to join by telephone for part of the meeting.</p> <p>Apologies were noted as above.</p>
JC18/046	<p><b>Declarations of Interest</b></p> <p>There were no declarations to note. The Joint Committee noted the standing declarations.</p>
JC18/047	<p><b>Accuracy of Minutes of the meeting held 10 July 2018</b></p> <p>The Joint Committee <b>approved</b> the minutes of the meeting held on 10 July 2018 as a true and accurate record.</p>
JC18/048	<p><b>Action Log</b></p> <p>The Joint Committee <b>received</b> the action log and noted the following updates:</p> <p><b>JC18003 – JC18/024 Integrated Commissioning Plan 2018-21: Work Plan</b> Update to be provided at the next meeting.</p> <p><b>JC18008 – JC18/039 Neuroscience Strategy Delivery Plan</b> IL reported the matter was on the agenda for the COO’s November meeting and an update would be provided at the next meeting.</p> <p><b>JC18009 - JC18/040 Integrated Performance Report</b> IL reported that Management Group had considered whether there was scope to revise tolerance levels and concluded that there was not – Action closed.</p> <p><b>Matters Arising</b> There were no matters arising.</p>
JC18/049	<p><b>Report from the Chair</b></p> <p>The Joint Committee <b>received</b> the report from the Chair.</p> <p>Members noted there was still a need for additional appointments to the Quality and Patient Safety Committee.</p> <p>Members noted the connection between WHSSC Quality and Patient Safety Committee and the Health Board Quality and Patient Safety Committees and how information flows between them would be an agenda item at a future Development Day. CB reported that the Chair’s Report and the minutes of the WHSSC Quality and Patient Safety</p>

	<p>Committee meetings were already being sent directly to the Chairs of the Health Board Quality and Safety Committees.</p> <p>The members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Note</b> the contents of the Report;</li> <li>• <b>Approve</b> the appointments of Maggie Berry and Lyn Meadows as Independent Members of the Quality and Patient Safety Committee;</li> <li>• <b>Approve</b> the appointment of Dr Christopher Jones as a Member and Vice Chair of the All Wales (WHSSC) Individual Patient Funding Review Panel;</li> <li>• <b>Approve</b> the Quality and Patient Safety Committee Terms of Reference</li> </ul>
JC18/050	<p><b>Report from the Managing Director</b> The Joint Committee <b>received</b> the report from the Managing Director.</p> <p>SL drew attention to the following items within the report which the Members discussed further:</p> <ul style="list-style-type: none"> <li>• Management Group Review: Members noted that the OD Team at CTUHB would be running an OD exercise with members of Management Group which would begin during autumn.</li> <li>• Mother &amp; Baby Unit for south Wales: WHSSC has received expressions of interest from two health boards to provide a Mother &amp; Baby Service and would be working with Public Health Wales on demand and flow.</li> <li>• Neonatal Transport: ABMUHB had expressed offered to act as lead provider.</li> </ul> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Note</b> the contents of the report.</li> </ul>
JC18/051	<p><b>Commissioning Intentions for 2019-22 Integrated Commissioning Plan</b> The Joint Committee <b>received</b> the paper outlining the options for Commissioning Intentions to inform the development of the WHSSC three year Integrated Commissioning Plan for Specialised Services 2019-22.</p> <p>IL reported the Commissioning Intentions had been refined, taking into account previous feedback, other systems and how other bodies across NHS Wales and the UK present their Commissioning Intentions, and tested at the August Management Group meeting. Members noted and discussed the 5 Commissioning Intentions set out in Table 1 of the paper and the respective measures of achievement.</p> <p>Members resolved to:</p>

	<ul style="list-style-type: none"> <li>• <b>Approve</b> the WHSSC Commissioning Intentions and their use to inform the development of the WHSSC Integrated Commissioning Plan 2019-22.</li> </ul>
JC18/052	<p><b>Introduction of Blueteq System for High Cost Drug Management</b> The Joint Committee <b>received</b> the paper that described the potential use of Blueteq management software in the commissioning of high cost drugs within NHS Wales.</p> <p>Members noted the introduction of the Blueteq system was being driven by the increased use of Managed Access Agreements for the provision and assessment of high costs drugs. Members further noted the support of Welsh Government, the All Wales Pharmacy Group and the All Wales Procurement specialist pharmacist for the acquisition of the Blueteq system.</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Note</b> the benefits of introducing the Blueteq high costs drug management system across NHS Wales</li> <li>• <b>Approve</b> recurrent funding for a system which supports both the 7 local health boards and WHSSC.</li> </ul>
JC18/053	<p><b>Terms of Reference – Integrated Governance Committee</b> The Joint Committee <b>received</b> the draft Terms of Reference for the Integrated Governance Committee. Members noted the Integrated Governance Committee had considered the draft Terms of Reference at a meeting on 12 June 2018 and approved them for onward consideration by the Joint Committee.</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Approve</b> the Terms of Reference for the Integrated Governance Committee.</li> </ul>
JC18/054	<p><b>Sub-Committee and Advisory Group Annual Reports</b> The Joint Committee received the Annual Reports from Management Group, Integrated Governance Committee, All Wales Individual Patient Funding Request Panel and Welsh Renal Clinical Network.</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Approve</b> the Annual Reports from Management Group, Integrated Governance Committee, All Wales Individual Patient Funding Request Panel and Welsh Renal Clinical Network.</li> </ul>

The meeting concluded at 10:55

JC18/055	<p><b>Integrated Performance Report</b> The Joint Committee <b>received</b> the June 2018 Integrated Performance Report.</p> <p>Members discussed the new format of the report.</p> <p>Members noted that the WHSS Team were holding monthly Cardiac Surgery performance management meetings with CVUHB.</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Note</b> June performance and the action undertaken to address areas of non-compliance</li> </ul>
JC18/056	<p><b>Financial Performance Report</b> The Joint Committee <b>received</b> the Financial Performance Report for Month 4 2018/19.</p> <p>Members noted the financial position reported in Month 4 for WHSSC was an over spend of £12k to date with a forecast over spend to year-end of £1,019k. The movements were across various budget headings, including overspend in Wales and deterioration in non-Welsh contracts, offset by underspends in Mental Health. In addition, the overall position had benefitted from the release of year end provisions.</p> <p>Members noted uncertainty remained regarding the risk of HRG4+ price increases proposed and reported by NHS England providers and their applicability to Wales.</p> <p>Members resolved to:</p> <ul style="list-style-type: none"> <li>• <b>Note</b> the current financial position and forecast year-end position.</li> </ul>
JC18/057	<p><b>Reports from the Joint Sub-Committees</b></p> <p><b>Management Group Briefings</b> The Joint Committee <b>received</b> the Management Group Briefings from the meetings held on 26 July 2018 and 23 August 2018.</p> <p><b>Integrated Governance Committee</b> The Joint Committee <b>received</b> the report.</p> <p><b>All Wales Individual Patient Funding Request Panel</b> The Joint Committee <b>received</b> the report.</p>
JC18/058	<p><b>Reports from the Joint Advisory Groups</b></p> <p><b>NHS Wales Gender Identity Partnership Group</b> The Joint Committee <b>received</b> the report.</p>

JC18/059	<p><b>Gender Identity Services</b></p> <p>CB reported Dr Sophie Quinney, a GP, had been appointed as WHSSC Associate Medical Director for Gender Identity.</p> <p>CB reported a number of members of the All Wales Gender Identity Partnership Group, including SQ would be attending the British Association of Gender Identity Specialists ('BAGIS') Scientific Symposium in Belfast, 4-5 October 2018, the first time there would be Welsh representation and that NHS Wales had been asked to host next year's Symposium.</p> <p>Members noted the formation of a Task and Finish Group led by Dr Mark Griffiths.</p>
JC18/060	<p><b>Date and Time of Next Meeting</b></p> <p>The Joint Committee noted the date of an extra ordinary meeting on 18 September 2018 at 17:00 for the purpose of discussing the thoracic surgery consultation.</p> <p>The Joint Committee noted the date of the next scheduled meeting as 13 November 2018 at 09:30.</p>

**Chair's Signature:** .....

**Date:** .....